Recommandations françaises du Comité de Cancérologie de l’AFU – Actualisation 2018–2020 : cancer de la prostate
- 1 November 2018
- journal article
- research article
- Published by Elsevier BV in Progrès en Urologie
- Vol. 28, R81-R132
- https://doi.org/10.1016/j.purol.2019.01.007
Abstract
No abstract availableKeywords
This publication has 262 references indexed in Scilit:
- HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG)Human Genetics, 2012
- Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyThe Lancet Oncology, 2012
- ESUR prostate MR guidelines 2012European Radiology, 2012
- Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyThe Lancet, 2011
- Long‐term survival after radical prostatectomy versus external‐beam radiotherapy for patients with high‐risk prostate cancerCancer, 2011
- Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adultsCritical Reviews in Oncology/Hematology, 2009
- Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancerNature Medicine, 2009
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other CancersJAMA, 2009